| Literature DB >> 30504444 |
Rodrigo Coutinho de Almeida1, Yolande F M Ramos1, Ahmed Mahfouz2,3, Wouter den Hollander1, Nico Lakenberg1, Evelyn Houtman1, Marcella van Hoolwerff1, H Eka D Suchiman1, Alejandro Rodríguez Ruiz1, P Eline Slagboom1, Hailiang Mei4, Szymon M Kiełbasa1,4, Rob G H H Nelissen5, Marcel Reinders1,2, Ingrid Meulenbelt6.
Abstract
OBJECTIVE: To uncover the microRNA (miRNA) interactome of the osteoarthritis (OA) pathophysiological process in the cartilage.Entities:
Keywords: data integration; mRNA; microRNAs; osteoarthritis; regulatory networks
Mesh:
Substances:
Year: 2018 PMID: 30504444 PMCID: PMC6352405 DOI: 10.1136/annrheumdis-2018-213882
Source DB: PubMed Journal: Ann Rheum Dis ISSN: 0003-4967 Impact factor: 19.103
Figure 1Data integration approach. Relative log normalised miRNA and mRNA expression matrices were concatenated. Next, differentially expressed miRNAs and genes were correlated and integrated according to the opposite direction of its FC. Further, miRNA–mRNA interactions from prediction tools and experimentally validated databases were integrated. Finally, target genes that followed these criteria were considered to build an OA miRNA–mRNA network. DE, differential expression; FC, fold change; miRNA, microRNA; mRNA, messenger RNA; OA, osteoarthritis.
Figure 2Paired differential expression analyses between preserved and lesioned OA cartilage. (A) Volcano plot with the differentially expressed miRNAs. (B) Volcano plot with the differentially expressed genes. Blue circles represent downregulated miRNAs (A) or genes (B); circles are red when they are upregulated. Labelled are the top differentially expressed genes and miRNAs, as well as the known and novel discovered ones. FC, fold change; FDR, false discovery rate; miRNA, microRNA; OA, osteoarthritis.
Pathways enrichment analysis of differentially expressed genes
| Term | P values | FWER | Fold enrichment | Genes |
| Extracellular matrix organisation | 1.82E-07 | 5.99E-05 | 5.20 | MATN4, POSTN, VIT, COL9A1, LAMB3, TNFRSF11B, FBLN1, COL19A1, COL7A1, FOXF1, TNR, SERPINE1, TGFBI, LAMC2, VCAN, SPP1, FN1 |
| Skeletal system development | 3.07E-06 | 1.01E-03 | 5.69 | BMP3, NOG, SOX11, POSTN, NPR3, FRZB, PAX1, TNFRSF11B, COL19A1, GDF10, VCAN, BMPR1B, BMP6 |
| Cell adhesion | 8.94E-05 | 2.93E-02 | 2.74 | AMTN, POSTN, AJAP1, CDH6, TNFAIP6, LAMB3, WISP2, COL19A1, COL7A1, LSAMP, TNR, MSLN, TGFBI, DSC3, RELN, LAMC2, VCAN, CHL1, SPP1, FN1, AOC3 |
| Positive regulation of gene expression | 1.30E-04 | 4.25E-02 | 3.43 | ODAM, WNT16, NOG, TESC, SOX11, IQGAP3, KIT, HMGA2, RIMS1, NTRK3, INHBA, FBLN1, ANK3, NGF, FN1 |
FWER, familywise error rate.
Figure 3OA miRNA–mRNA interactome. Network of differentially expressed miRNAs targeting differentially expressed genes between unaffected (preserved) and lesioned OA cartilage. Diamonds are miRNAs and circles genes; edges denote that an miRNA targets the connected gene. The size of the nodes is proportional to the number of edges (interactions). Node colour characterises the strength and the direction of the expression change between unaffected (preserved) and lesioned OA cartilage. Edge thickness corresponds to Pearson’s correlation between the miRNA and gene across all samples. miRNA, microRNA; mRNA, messenger RNA; OA, osteoarthritis.
Figure 4Functional validation miRNA–mRNA interactions. (A) Expression of AMIGO1, SMAD3, GHR and DCAKD in primary chondrocytes transfected with miR-143–3 p mimic or antagomir compared with control as determined by RT-qPCR. (B) Expression of WNT9A, FZD1 and GDF6 in primary chondrocytes transfected with miR-329–3 p or miR-99a-3p mimic or antagomir compared with control as determined by RT-qPCR. Data shown are the average±SE of the mean for three independent donors (*p<0.05). miRNA, microRNA; mRNA, messenger RNA; RT-qPCR, reverse transcriptase-quantitative PCR.
Pathway analysis of differentially expressed target genes
| Term | P values | FWER | Fold enrichment | Genes |
| Positive regulation of GTPase activity | 4.60E-08 | 9.80E-06 | 7.68 | SNX18, PDGFA, ARHGEF17, S100A10, IRS1, RAB3IP, ELMO1, THY1, FZD10, RGS4, RASA3, ST5, TBC1D20, SRGAP1 |
| Nervous system development | 3.93E-07 | 8.37E-05 | 7.07 | GLRB, NTF3, PCDHB4, NLGN1, NINJ1, EVL, SLC7A5, CSGALNACT1, BZW2, TPP1, DLG3, CRIM1, DCLK1 |
| Protein phosphorylation | 5.66E-06 | 1.20E-03 | 5.46 | RPS6KA5, CCNE1, CCND1, PKN3, WNK4, PHKG2, MKNK2, TESK2, PRKACA, PRKACB, BMPR1B, DCLK1, TRIB2 |
| IRE1-mediated unfolded protein response | 6.84E-06 | 1.46E-03 | 102.27 | TPP1, SRPRB, SEC61A1, ADD1 |
| Stimulatory C-type lectin receptor signalling pathway | 6.84E-06 | 1.46E-03 | 102.27 | RPS6KA5, PSMD1, PRKACA, PRKACB |
| Extracellular matrix organisation | 9.93E-06 | 2.11E-03 | 5.16 | PDGFA, LUM, ADAMTSL4, TNC, ITGB4, SPINT1, ITGB5, ITGA3, CSGALNACT1, COL9A1, ITGA5, COL27A1, TGFBI |
| Signal transduction | 1.96E-05 | 4.17E-03 | 3.06 | PTPRK, OSTF1, NTF3, CYTL1, MAPKAPK3, PDE3B, TNFSF13, CDS1, IRS1, SUFU, PLAUR, TMED4, MYD88, EPS8, PKN3, SMOC1, PDE8B, IGFBP1, PRKACB, RASA3, SRGAP1 |
| Tumour necrosis factor-mediated signalling pathway | 1.11E-04 | 2.36E-02 | 42.61 | TNFRSF12A, PSMD1, TNFRSF19, TNFSF13 |
| Activation of protein kinase A activity | 1.50E-04 | 3.19E-02 | 153.41 | PRKAR2B, PRKACA, PRKACB |
| Cellular response to BMP stimulus | 2.18E-04 | 4.65E-02 | 34.09 | SPINT1, TMEM100, BMPR1B, BMP6 |
*p<0.05.
BMP, bone morphogenic protein; FWER, familywise error rate.